Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Assets (2016 - 2025)

Historic Current Assets for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $429.1 million.

  • Iovance Biotherapeutics' Current Assets changed N/A to $429.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year change of. This contributed to the annual value of $457.0 million for FY2024, which is 4845.57% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Current Assets of $429.1 million as of Q3 2025.
  • In the past 5 years, Iovance Biotherapeutics' Current Assets ranged from a high of $637.8 million in Q1 2023 and a low of $274.9 million during Q2 2023
  • For the 3-year period, Iovance Biotherapeutics' Current Assets averaged around $423.3 million, with its median value being $422.5 million (2025).
  • Over the last 5 years, Iovance Biotherapeutics' Current Assets had its largest YoY gain of 4845.57% in 2024, and its largest YoY loss of 3955.09% in 2024.
  • Over the past 3 years, Iovance Biotherapeutics' Current Assets (Quarter) stood at $307.8 million in 2023, then skyrocketed by 48.46% to $457.0 million in 2024, then fell by 6.11% to $429.1 million in 2025.
  • Its Current Assets stands at $429.1 million for Q3 2025, versus $422.5 million for Q2 2025 and $512.6 million for Q1 2025.